However, their cohort contained patients receiving BRAFi monotherapy as well as combined MAPKi and included ~50% of patients who were not treatment nave
However, their cohort contained patients receiving BRAFi monotherapy as well as combined MAPKi and included ~50% of patients who were not treatment nave. == Results == OS was significantly longer in patients receiving anti-PD-1 monotherapy compared to patients receiving combined MAPK inhibitors. Subsequent therapies were comparable among these groups. The difference in OS was less pronounced in patients with high LDH levels and visceral metastatic spread. == Conclusion == First-line treatment with a PD-1 blocking antibody might be associated with longer OS than first-line inhibition of the MAPK pathway in patients with advanced melanoma harboring mutant BRAF. These hypothesis-generating data need to be confirmed or rejected in prospective, randomized trials. == Electronic supplementary material == The online version of this article (10.1007/s00262-019-02311-1) contains supplementary material, which is available to authorized…